Sentence examples for both a prognostic marker from inspiring English sources

miR-134 may represent both a prognostic marker and a novel therapeutic target for this malignancy.

This emphasises the role of renal function as both a prognostic marker as well as a potential therapeutic target in the treatment of atherosclerotic disease.

Cathelicidin LL37 is a promising new biomarker for active AAV, including aggressive crescentic glomerulonephritis, and may prove to be both a prognostic marker and a guide for treatment.

HER1 (or EGFR) has been described as both a prognostic marker and a predictor of hormone-therapy resistance in breast cancer [ 55].

For instance, the 500C>T polymorphism has been heavily studied in breast, colorectal, gastric, glioma, lung and prostate cancers as both a prognostic marker and a predictive marker for platinum therapeutic outcomes in a multitude of individuals with different racial backgrounds.

Aurora A kinase, EGFR, AKT/PI3K, MYC amplification and TOP2A gene copy number deletion or mutation has been significantly associated with several clinicopathological parameters and poor prognosis in breast cancer patients and are both a prognostic marker for poor outcome [ 71, 74, 75].

These findings raise the possibility that ACOX2-i9 may both be a prognostic marker and a potential therapeutic target.

Stein et al. [ 2] report the association of overexpression of MACC1 with an increased risk for CRC metastasis, providing compelling data that this gene may be useful both as a prognostic marker and possibly as a chemopreventive or therapeutic target.

The value of RPN2, both as a prognostic marker and as a therapeutic target is suggested for future validation.

It is concluded that s-dTk could be used both as a prognostic marker and to monitor the effect of therapy in NHL patients.

Within the context of trastuzumab-based therapy, the measurement of serum Her2/neu ECD has generated an increasing interest to understand the precise biological function of the soluble Her2/neu portion in cancer development as well as its clinical implications in the management of patients eligible for trastuzumab therapy, both as a prognostic marker and as a predictor of response to treatment.